

October 29, 2024

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir/ Madam,

Sub: Press Release - Hon'ble Prime Minister Shri Narendra Modi Inaugurates Lyfius Pharma's Flagship Penicillin-G Facility at Kakinada, Andhra Pradesh

We enclose a copy of the Press Release that is being issued by Lyfius Pharma Private Limited, a wholly owned step-down subsidiary of the Company, in connection with inauguration of its Flagship Penicillin-G Facility by **Hon'ble Prime Minister Shri Narendra Modi**.

Please take the information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary

Encl: as above

(CIN : L24239TG1986PLC015190)

AUROBINDO PHARMA LIMITED
www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad -500038 T.S., INDIA Tel: +91 4023736370/23747340 Fax: +91 4023741080/23746833
Email: info@aurobindo.com Website: www.aurobindo.com

Hon'ble Prime Minister Shri Narendra Modi Inaugurates Lyfius Pharma's Flagship Penicillin-G Facility at Kakinada, Andhra Pradesh

- Under the Production Linked Incentive (PLI) scheme, Lyfius Pharma Private Limited (Lyfius Pharma) invested ₹2,500 crores in Penicillin-G (Pen-G) facility
- Commercial production to ramp up in FY25, enhancing domestic production of critical Key Starting Materials (KSMs), Drug Intermediates (DIs), and Active Pharmaceutical Ingredients (APIs)

Kakinada, 29th October, 2024: Lyfius Pharma proudly announces the inauguration of its state-of-the-art Pen-G manufacturing facility, at Kakinada, Andhra Pradesh. With an annual production capacity of 15,000 metric tonnes (MT), the facility was virtually inaugurated by Hon'ble Prime Minister Shri. Narendra Modi in the presence of Shri. Jagat Prakash Nadda (Union Minister of Chemicals & Fertilizers, Health & Family Welfare), Dr. Mansukh Mandaviya (Union Minister of Labour & Employment, Youth Affairs & Sports), Smt. Anupriya Patel (Union MoS Chemicals & Fertilizers, Health & Family Welfare), Shri. Prataprao Jadhav (Union MoS (IC) Ayush, MoS Health & Family Welfare) and Sushri Shobha Karandlaje (Union MoS Labour & Employment, Micro, Small & Medium Enterprises).

This facility represents a strategic investment of ₹2,500 crores, under the Government of India's PLI Scheme, and exemplifies how private sector participation can significantly contribute to national growth, drive innovation, and enhance healthcare security. The PLI scheme for the pharmaceutical sector aims to strengthen domestic manufacturing capabilities in critical KSMs, DIs, and APIs.

Commenting on the occasion, **Mr. M.V. Rama Krishna, Director Lyfius Pharma**, said *"The launch of our Pen-G facility is a significant milestone in our efforts to enhance local production and reduce import dependency for critical pharmaceutical ingredients. This investment underscores our commitment to support the government's vision of 'Atmanirbhar Bharat', establishing India as a global pharmaceutical manufacturing hub."*

About Lyfius Pharma Private Limited

Lyfius Pharma is engaged in the manufacturing of Penicillin-G. Its state-of-art facility situated at Kakinada, Andhra Pradesh, approved under the PLI (Production Linked Incentive) scheme, is dedicated towards ensuring self-sufficiency in the production of Penicillin-G, catering to both the domestic and international markets. This is one of the largest fermentation-based antibiotic intermediates plant in India with cutting edge technology including high-volume fermenters and automated starch & glucose plant.

Disclaimer:

This press release contains statements that may constitute "forward looking statements" including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward-looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward-looking statements to reflect future events or circumstances and will not be held liable for any use of this information.

LYFIUS PHARMA PRIVATE LIMITED

CIN No. U24299AP2020PTC116443

PAN No. AAEC14415B

Reg.Off.: Unit-14, JN Pharma City, Plot No. 17, R No. 10,11 & 19,20 E-Bonangi Village, Visakhapatnam - 531021, Andhra Pradesh, India.

Tel : +91 8924-236171, 8924-236091

Plant Address : Sy. No.350,351,353,354-358,361-375,380-382, A.V. Nagaram (V), kakinada SEZ area, Thondangi (M), Kakinada District - 533449, Andhra Pradesh, India.